Get started
Author

Olaf Valverde Mordt

Observed names: OV Mordt, Valverde Mordt, O.
ORCID: 0000-0002-3898-1014
Observed ORCID: 0000-0002-3898-1014
OpenAlex ID: A5090892765
Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial
2017 · Victor Kande Betu Ku Mesu, Wilfried Mutombo Kalonji, et al. · The Lancet · 291
PDF
Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial
2022 · Victor Kande Betu Kumeso, Wilfried Mutombo Kalonji, et al. · The Lancet Infectious Diseases · 137
PDF
Determination of an Optimal Dosing Regimen for Fexinidazole, a Novel Oral Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Studies
2014 · Antoine Tarral, Séverine Blesson, et al. · Clinical Pharmacokinetics · 107
PDF
Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study
2021 · Victor Kande Betu Ku Mesu, Wilfried Mutombo Kalonji, et al. · The Lancet Global Health · 59
PDF
In-Hospital Safety in Field Conditions of Nifurtimox Eflornithine Combination Therapy (NECT) for T. b. gambiense Sleeping Sickness
2012 · Caecilia Schmid, Andrea Kuemmerle, et al. · PLoS neglected tropical diseases · 57
PDF
Determination of the Optimal Single Dose Treatment for Acoziborole, a Novel Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Study
2023 · Antoine Tarral, Lionel Hovsepian, et al. · Clinical Pharmacokinetics · 37
PDF
Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study
2021 · Andrea Kuemmerle, Caecilia Schmid, et al. · PLoS neglected tropical diseases · 35
PDF
Development and Introduction of Fexinidazole into the Global Human African Trypanosomiasis Program
2022 · Olaf Valverde Mordt, Antoine Tarral, et al. · American Journal of Tropical Medicine and Hygiene · 31
PDF
How Clinical Research Can Contribute to Strengthening Health Systems in Low Resource Countries
2020 · Florent Mbo, Wilfried Mutombo, et al. · Tropical Medicine and Infectious Disease · 26
PDF
Communities’ Perception, Knowledge, and Practices Related to Human African Trypanosomiasis in the Democratic Republic of Congo
2022 · Charlie Kabanga, Olaf Valverde Mordt, et al. · Diseases · 21
PDF
Fexinidazole as a new oral treatment for human African trypanosomiasis due to Trypanosoma brucei rhodesiense: a prospective, open-label, single-arm, phase 2–3, non-randomised study
2025 · Enock Matovu, Westain Nyirenda, et al. · The Lancet Global Health · 20
Safety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single-arm, open-label, phase 2–3 trial
2022 · Victor Kande Betu Kumesu, Wilfried Mutombo Kalonji, et al. · The Lancet Global Health · 20
Prescription of concomitant medications in patients treated with Nifurtimox Eflornithine Combination Therapy (NECT) for T.b. gambiense second stage sleeping sickness in the Democratic Republic of the Congo
2020 · Andrea Kuemmerle, Caecilia Schmid, et al. · PLoS neglected tropical diseases · 13
PDF
Trypanosome SL-RNA detection in blood and cerebrospinal fluid to demonstrate active gambiense human African trypanosomiasis infection
2021 · Ipos Ngay Lukusa, Nick Van Reet, et al. · PLoS neglected tropical diseases · 10
PDF
Effectiveness and safety of fexinidazole for gambiense human African trypanosomiasis and exploration of adherence in outpatients: a phase 3b, prospective, open-label, non-randomised, cohort study
2025 · Victor Kande Betu Kumeso, Christelle Perdrieu, et al. · The Lancet Global Health · 8
Trypanosome spliced leader RNA for diagnosis of acoziborole treatment outcome in gambiense human African trypanosomiasis: A longitudinal follow-up study
2022 · Ipos Ngay Lukusa, Nick Van Reet, et al. · EBioMedicine · 8
A DBS Method for Quantitation of The New Oral Trypanocidal Drug Fexinidazole and its Active Metabolites
2016 · Aziz Filali-Ansary, Cécile Augé, et al. · Bioanalysis · 6
Exploring barriers to seeking treatment for human African trypanosomiasis due to T.b. rhodesiense in communities around Vwaza Marsh Wildlife Reserve in Rumphi and Mzimba Districts, northern Malawi
2023 · Alister C. Munthali, Marshal Lemelani, et al. · medRxiv · 2
PDF
Towards an arsenic-free oral treatment for human African trypanosomiasis due to Trypanosoma brucei rhodesiense: a new tool for disease elimination
2024 · E Baudin, OV Mordt, et al. · 1
PDF
Towards an arsenic-free oral treatment for human African trypanosomiasis due to Trypanosoma brucei rhodesiense a new tool for disease elimination
2024 · E Baudin, OV Mordt, et al. · 1
PDF
OA-504 Towards an arsenic-free oral treatment for human African trypanosomiasis due to Tb rhodesiense: a new tool for disease elimination
2023 · Olaf Valverde Mordt, Deolinda Alves, et al. · BMJ Global Health
PDF
PA-580 Capacity development to facilitate delivery and uptake of a new medical intervention: fexinidazole oral treatment for the elimination of human African trypanosomiasis
2023 · Florent Mbo, Digas Ngolo, et al. · BMJ Global Health
PDF
Works count: 25
Citation count: 890
H-index: 13
I10-index: 14
Year
Topic
Type